Edward Piper

1.1k total citations
14 papers, 885 citations indexed

About

Edward Piper is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Infectious Diseases. According to data from OpenAlex, Edward Piper has authored 14 papers receiving a total of 885 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Physiology, 8 papers in Pulmonary and Respiratory Medicine and 2 papers in Infectious Diseases. Recurrent topics in Edward Piper's work include Asthma and respiratory diseases (10 papers), Respiratory and Cough-Related Research (6 papers) and Inhalation and Respiratory Drug Delivery (5 papers). Edward Piper is often cited by papers focused on Asthma and respiratory diseases (10 papers), Respiratory and Cough-Related Research (6 papers) and Inhalation and Respiratory Drug Delivery (5 papers). Edward Piper collaborates with scholars based in United Kingdom, United States and Sweden. Edward Piper's co-authors include Christopher E. Brightling, Dewei She, Richard May, Stephanie Korn, Pascal Chanez, Paul M. O’Byrne, Richard Leigh, Koustubh Ranade, Katie Streicher and Raffaella Faggioni and has published in prestigious journals such as Circulation, American Journal of Respiratory and Critical Care Medicine and Gut.

In The Last Decade

Edward Piper

12 papers receiving 851 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edward Piper United Kingdom 8 691 404 326 213 154 14 885
Sophie Pégorier United Kingdom 8 295 0.4× 189 0.5× 261 0.8× 74 0.3× 135 0.9× 9 615
Arzu Didem Yalçın Türkiye 15 192 0.3× 118 0.3× 152 0.5× 122 0.6× 43 0.3× 68 585
Frauke Pedersen Germany 15 297 0.4× 330 0.8× 221 0.7× 56 0.3× 46 0.3× 31 655
Timo Effenberger Germany 5 171 0.2× 123 0.3× 79 0.2× 41 0.2× 42 0.3× 6 348
E Tanabe Japan 10 214 0.3× 18 0.0× 259 0.8× 39 0.2× 55 0.4× 20 460
Lindsay Hosford United States 12 68 0.1× 145 0.4× 184 0.6× 20 0.1× 307 2.0× 22 532
J.G. Dohlman United States 8 64 0.1× 38 0.1× 149 0.5× 20 0.1× 49 0.3× 8 448
Elisa Gómez Spain 9 108 0.2× 18 0.0× 231 0.7× 64 0.3× 16 0.1× 14 602
Susanne Wangler Germany 10 38 0.1× 29 0.1× 556 1.7× 49 0.2× 108 0.7× 12 710
Paloma Gil-Bernabe Japan 12 78 0.1× 143 0.4× 107 0.3× 12 0.1× 32 0.2× 13 367

Countries citing papers authored by Edward Piper

Since Specialization
Citations

This map shows the geographic impact of Edward Piper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Piper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Piper more than expected).

Fields of papers citing papers by Edward Piper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward Piper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Piper. The network helps show where Edward Piper may publish in the future.

Co-authorship network of co-authors of Edward Piper

This figure shows the co-authorship network connecting the top 25 collaborators of Edward Piper. A scholar is included among the top collaborators of Edward Piper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward Piper. Edward Piper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Panettieri, Reynold A., Ulf Sjöbring, Peter Wessman, et al.. (2018). Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. The Lancet Respiratory Medicine. 6(7). 511–525. 177 indexed citations
2.
Baverel, Paul, Dewei She, Edward Piper, et al.. (2017). A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers. Drug Metabolism and Pharmacokinetics. 33(3). 150–158. 15 indexed citations
3.
Brightling, Christopher E., Edward Piper, Peter Wessman, & Gene Colice. (2017). Effect of tralokinumab on GINA control in severe, uncontrolled asthma. PA4683–PA4683. 1 indexed citations
4.
Brightling, Christopher E., Lars H. Nordenmark, Meena Jain, et al.. (2016). Effect of Anti–IL-13 Treatment on Airway Dimensions in Severe Asthma. American Journal of Respiratory and Critical Care Medicine. 194(1). 118–120. 10 indexed citations
5.
Ranade, Koustubh, Michael Kuziora, Tuyet‐Hang Pham, et al.. (2016). Dipeptidyl peptidase-4 (DPP-4) may predict response to tralokinumab in patients with asthma. OA1796–OA1796. 1 indexed citations
6.
Brightling, Christopher E., Pascal Chanez, Richard Leigh, et al.. (2015). Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet Respiratory Medicine. 3(9). 692–701. 285 indexed citations
7.
Brightling, Christopher E., Lars H. Nordenmark, Meena Jain, et al.. (2015). Effect of anti-IL-13 treatment on airway dimensions in severe asthma: Subgroup analysis. PA2119–PA2119.
8.
Baverel, Paul, Meena Jain, Iwona Stelmach, et al.. (2015). Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing. British Journal of Clinical Pharmacology. 80(6). 1337–1349. 23 indexed citations
9.
Piper, Edward, Christopher E. Brightling, Robert Niven, et al.. (2012). A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. European Respiratory Journal. 41(2). 330–338. 290 indexed citations
10.
11.
Piper, Edward, Christopher E. Brightling, Robert Niven, et al.. (2011). Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma. European Respiratory Journal. 38(Suppl 55). 3425–3425. 7 indexed citations
12.
Stein, Evan A., et al.. (2011). Lapaquistat Acetate. Circulation. 123(18). 1974–1985. 54 indexed citations
13.
Misiewicz, J J, S. L. Waller, M. J. R. Healy, & Edward Piper. (1968). Computer analysis ofintraluminal pressure records.
14.
Misiewicz, J J, S. L. Waller, M. J. R. Healy, & Edward Piper. (1968). Computer analysis of intraluminal pressure records.. Gut. 9(2). 232–236. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sophie Pégorier Breakdown of academic impact, for papers by Arzu Didem Yalçın Breakdown of academic impact, for papers by Frauke Pedersen Breakdown of academic impact, for papers by Timo Effenberger Breakdown of academic impact, for papers by E Tanabe Breakdown of academic impact, for papers by Lindsay Hosford Breakdown of academic impact, for papers by J.G. Dohlman Breakdown of academic impact, for papers by Elisa Gómez Breakdown of academic impact, for papers by Susanne Wangler Breakdown of academic impact, for papers by Paloma Gil-Bernabe
Rankless by CCL
2026